News Sentiment

COLL sentiment intelligence

Collegium Pharmaceutical Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 50 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 33.54 Week of 19 Jun 2026
Weighted tone 55/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

85/100 classification confidence.

Company focus 50

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-3.2% over one week, -1.6% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

Did Collegium Pharmaceutical’s Profitability Surge and Efficiency Gains Just Shift COLL’s Investment Narrative?

Market Reaction

Balanced read

66/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 85/100 classification
One-week reaction -3.2% Price reacting lower
Trend fit Trend inactive -1.6% over four weeks
Fair value 1.2% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 34
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 50
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 16
TradingKey 9
Market source 7
Simply Wall Street 6
simplywall.st 4
GlobeNewswire 2
Stock Traders Daily 1
lwvtexas.org 1

Event Lens

What the news is about

Classified themes
Market update 35
Earnings 10
Deals and strategy 2
Balance sheet 1
Guidance 1
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-50 of 50
Stock Titan Direct company coverage

Director Carlos V. Paya granted 8,741 RSUs at COLLEGIUM (NASDAQ: COLL)

COLLEGIUM PHARMACEUTICAL, INC. director Carlos V. Paya was granted 8,741 restricted stock units (RSUs) as compensation, increasing his direct holdings to 28,323 shares. These RSUs will vest on the earlier of May 14, 2027, or the company's 2027 Annual Meeting of Shareholders, cont

Tone
Neutral 50/100
Event
Market update
Published
19 May 2026 04:08
Source
Stock Titan
Stock Titan Direct company coverage

Director at Collegium (COLL) awarded 17,482 restricted stock units

Collegium Pharmaceutical director Michael Glancy was granted 17,482 restricted stock units (RSUs) on May 14, 2026, at no cash cost. These RSUs will vest in two equal tranches on or around May 14, 2027, contingent on his continued service to the board. Following this grant, Glancy

Tone
Neutral 50/100
Event
Balance sheet
Published
18 May 2026 20:08
Source
Stock Titan
Investing.com Direct company coverage

Collegium pharmaceutical director sells $142k in shares

A director at Collegium Pharmaceutical, John Gordon Freund, recently sold shares worth $142,546 and exercised stock options on May 14 and 15, 2026. Despite the stock being down 27% year-to-date, it has risen 12% over the past year. The company also reported strong Q1 2026 financi

Tone
Neutral 50/100
Event
Market update
Published
18 May 2026 20:08
Source
Investing.com
Stock Titan Direct company coverage

Collegium Pharmaceutical (COLL) director receives 8,741 RSU grant, now holds 71,000 shares

Collegium Pharmaceutical director Garen G. Bohlin was granted 8,741 Restricted Stock Units (RSUs), increasing his direct holdings to 71,000 shares. These RSUs, which represent one share of common stock each, will vest on the earlier of May 14, 2027, or the company's 2027 Annual M

Tone
Neutral 50/100
Event
Market update
Published
18 May 2026 20:08
Source
Stock Titan